62-Year-Old Man Becomes First Patient In China Implanted With Rechargeable Neurostimulator For Chronic Pain
St. Jude Medical, Inc. (NYSE:STJ) announced that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade. The Eon neurostimulator, which is the first rechargeable spinal cord stimulator to be approved for use in China, was recently approved by the Chinese State Food and Drug Administration (SFDA) for the management of chronic low back pain and pain from back surgeries that have failed. "Chronic pain is a serious health issue in China, " said Professor Zhang De Ren, M.
Women with incontinence, respiratory disorders and gastrointestinal problems have increased risk for development of back pain, according to research reported in The Journal of Pain, the peer review publication of the American Pain Society. Australian pain researchers reviewed case histories of some 7500 young, mid-age and older women who participated in the Australian Longitudinal Study of Women's Health who reported no back pain during the preceding 12 months. They were followed for up to four years. The study was intended to show that identifying some conditions that may predispose women to back pain later in life is one way to assist in prevention and help control the cost of a widespread and expensive health problem.
Osteoarthritis (OA) and degenerative disc disease (DDD) are common, chronic musculoskeletal disorders. Both diseases cause joint pain, loss of function, and decreased quality of life for the more than 27 million OA and 59 million DDD suffers in the US. According to a 2003 Medical Expenditure Panel Survey, arthritis such as OA costs the U.S. economy nearly $128 billion per year in medical care and indirect expenses including lost wages and productivity. Researchers at Duke University Medical Center, under a grant from the National Institutes of Health (NIH), conducted a study of mice to determine the effect of Type IX collagen (Col9a1) deficiency on functional ability.
US researchers studying people with chronic lower back problems found that those who did Iyengar Yoga were better at overcoming pain and depression than those who followed conventional treatments for lower back pain. The study, which was funded by the US National Institutes of Health to the tune of 400, 000 dollars, was the work of Dr Kimberly Williams, research assistant professor in the Department of Community Medicine at West Virginia University in Morgantown, and colleagues, and can be read online in the 1 September issue of the journal Spine. Low-back pain is the largest category for medical reimbursements in the US, accounting for 34 billion dollars of medical costs every year, said the researchers.
Geckos and other lizards have long been known for their incredible ability to shed their tails as a decoy for predators, but little is known about the movements and what controls the tail once it separates from the lizard's body. Anthony Russell of the University of Calgary and Tim Higham of Clemson University in South Carolina are closer to solving this mystery as outlined in a paper they co-authored published in the journal Biology Letters. The scientists demonstrate that tails exhibit not only rhythmic but also complex movements, including flips, jumps and lunges, after the tails are shed. Although one previous study has looked at movement of the tail after it is severed, no study up to this point has quantified movement patterns of the tail by examining the relationship between such patterns and muscular activity.
Mesoblast Limited ASX:MSB Proprietary Stem Cells Successfully Repair Regenerate Damaged Intervertebral Disc Cartilage
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced highly successful preclinical trial results of its adult stem cells in the treatment of degenerative intervertebral disc disease, the leading cause of low back pain. A single low-dose injection of Mesoblast's allogeneic or "off-the-shelf' adult stem cells into severely damaged intervertebral discs resulted in dramatic reversal of the degenerative process, regrowth of disc cartilage, and sustained normalization of disc pathology, anatomy and function. The results of a placebo-controlled, randomised trial of Mesoblast's cells for the treatment of degenerative disc disease in 36 sheep is being presented and highlighted at the World Congress on Osteoarthritis, OsteoArthritis Research Society International (OARSI), being held in Montreal, Canada from 10-12 September.